SinoMab BioScience (HKG:3681) agreed to issue a total of 112,810,817 shares to 26 subscribers at HK$1.10 apiece to raise net proceeds of nearly HK$124 million, a Tuesday Hong Kong bourse filing said.
The shares represent around 9.37% of the biopharmaceutical company's enlarged issued share capital.
The firm will use proceeds from the issue for R&D, clinical programs, and potential global cooperations of SM17; diversification of the product portfolio by carrying out research, trials, production, and more for new drug candidates; and general working capital.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。